| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2256 | Gka-22 | Novel Allosteric Activator of Human Glucokinase in the Absence of Glucose |
|
| DCC2257 | Gka-71 | Novel and potent glucokinase activator (GKA) |
|
| DCC2258 | Gkm001 | First-in-class liver-selective glucokinase activator for the treatment of type 2 diabetes |
|
| DCC2259 | glaziovianin A | Novel inhibitor of the cell cycle progression in M-phase; Inhibotor of endosome maturation |
|
| DCC2260 | Glenvastatin | Novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor |
|
| DCC2261 | Glft2-in-31 | Novel Galactofuranosyltransferase 2 (GlfT2) inhibitor |
|
| DCC2262 | Glipentide | Second-generation sulfonylurea, promoting the accumulation of fructose 2,6-bisphosphate in hepatocytes |
|
| DCC2263 | Glmu-in-5175178 | Novel inhibitor of the acetyltransferase activity of Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). |
|
| DCC2264 | Glo1-in-60 | Novel potent Glyoxalase 1 (GLO1) inhibitor, demonstrating to penetrate the blood-brain barrier, elevating levels of methylglyoxal in the brain, and reducing depression-like behavior in mice |
|
| DCC2265 | Glo1-in-9 | Novel inhibitor of glyoxalase 1 (Glo1), increasing the cellular methylglyoxal levels in human cells and suppressing the osteoclast formation of mouse bone marrow-derived macrophages |
|
| DCC2266 | Glp-2 (1-33) Acetate | Enteroendocrine hormone, stimulating the growth of intestinal epithelium |
|
| DCC2267 | Glp-2r Modulator I | Ago-allosteric modulator of human GLP-2R |
|
| DCC2268 | Glpg0259 | The first-in-class, ATP-competitive inhibitor of MAPKAPK5 |
|
| DCC2269 | Gls1 Inhibitor Ll202 | Novel inhibitor of glutaminase 1 (GLS1) with high binding affinity (SPR, Kd = 24 nM; ITC, Kd = 37 nM), exhibiting a similar in vivo antitumor activity as CB839 |
|
| DCC2270 | Glut4-activator-26b | Novel potent glucose transporter type 4 (GLUT4) translocation activator, showing a significant blood glucose lowering effect in the severe diabetic mice model |
|
| DCC2271 | Glut-i1 | Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4) |
|
| DCC2272 | Glut-i2 | Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4) |
|
| DCC2273 | Glut-i2-nh2 | Glucose transporter inhibitor linker for insulin conjugate |
|
| DCC2274 | Glut-in-30 | Novel glucose transporter (GLUT) inhibitor, exhibited high antitumor potency through the suppression of glucose uptake (IC 50 : 2.5 μM), while not cytotoxic to prostate and mammary epithelial cells |
|
| DCC2275 | Glycitin 6"-o-malonate | Metabolite of soy isoflavones, promoting the proliferation of bone marrow stromal cells and osteoblasts and suppresses bone turnover |
|
| DCC2276 | Gm3 N-12 | Novel GM3 derivative, showing excellent migration and invasion inhibitory effects in cells and marked antitumor activity in C57BL/6 mice, involving focal adhesion and ECM-receptor interaction signaling pathways |
|
| DCC2277 | Gma-839 | Selective modulator of gamma-aminobutyric acid(A) receptors |
|
| DCC2278 | Gmb-805 | Novel potent BCR-Abl PROTAC, inducing degradation and demonstrating in vivo activity |
|
| DCC2279 | Gmb-905 | Negative control for GMB-805 |
|
| DCC2280 | Gn39482 | Novel Tubulin Polymerization Inhibitor |
|
| DCC2281 | Gne-0723 | Novel GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of The N-methyl-d-aspartate receptor (NMDAR) |
|
| DCC2282 | Gne-0946 | Novel potent and selective RORc inverse agonist |
|
| DCC2283 | Gne-203 | Novel Met inhibitor |
|
| DCC2284 | Gne-3476 | Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM) |
|
| DCC2285 | Gne-5729 | Novel NMDAR PAM with both an improved pharmacokinetic profile and increased selectivity against AMPARs |
|
